Gregg W Stone
Professor of Medicine, Professor of Population Health Sciences and Policy, and Director of Academic Affairs
Mount Sinai, New York, US
Dr. Stone grew up in the Shaker Heights suburb of Cleveland, Ohio. His mother was a housewife who had gone to Ohio State University at the age of 15 before meeting his father, who owned an advertising firm. Dr. Stone claims to have had an innate curiosity for how things work from a very young age, which led him to research science and conduct experiments throughout his youth in the home chemistry lab of his parents’ garage. He met his wife, Dr. Amy E. Stone, MD, whilst completing his cardiology fellowship at Cedars-Sinai Medical Centre in Los Angeles. Dr. Gregg Stone currently resides in Greenwich, Connecticut.
Dr. Stone completed high school in Ohio, where his principal interest was chemistry, before continuing his study at the University of Michigan where he discovered his interest in medical research. He then studied his medical degree at Johns Hopkins University in Baltimore, Maryland, under the tutelage of renowned medical professionals such as Dr. Myron Weisfeldt. After his education at Johns Hopkins University, Dr. Stone then commenced his internship and residency at NewYork-Presbyterian Weill Cornell Medical Center, after which he carried out two cardiology fellowships; one at Cedars-Sinai Medical Centre in Los Angeles, under the late Dr. Jeremy Swan, and a second at the Saint Luke's Mid America Heart Institute in Kansas under the tutelage of the late Dr. Geoffrey O. Hartzler.
Dr. Stone has become a leading expert in interventional cardiology and is one of the most widely cited researchers on the topic. He has served as the principal investigator for approximately 100 national and international multicenter randomized trials, has delivered thousands of lectures internationally, and has authored over 2,000 book chapters, manuscripts and abstracts published in peer-reviewed literature.
Dr. Stone previously worked as the Director of Interventional Cardiology at the Cardiovascular Institute at El Camino Hospital and Stanford University Medical Center in California, where he set up a research division of around 11 physicians and became involved with Primary Angioplasty in Myocardial Infarction (PAMI) studies.
He then moved to Washington D.C. to work as the Director of the Cardiovascular Training and Education Center at the Washington Hospital Center, at the request of Dr. Martin Leon. Dr. Stone worked there for a year, where he would spend up to 4 hours a day with the world’s leading cardiology experts learning about interventional cardiology and advancing research in the area. He also became a Director of the Transcatheter Cardiovascular Therapeutics (TCT), which is the world's largest symposium focused on interventional cardiology and vascular medicine. Dr. Stone then brought the whole Cardiovascular Research Foundation to New York and partnered with Lenox Hill Hospital, where he furthered his research into interventional cardiology.
Big news followed next, as Dr. Gregg Stone followed Dr. Jeffrey Moses and Dr. Martin Leon to move uptown to Columbia University Medical Center/New York Presbyterian Hospital, where he was appointed Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy, and Professor of Medicine at the Columbia University Irving Medical Center. Dr. Stone now fulfills the position of Professor of Medicine and Professor of Population Health Sciences and Policy at The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine, at Mount Sinai, as well as being the Director of Academic Affairs for Mount Sinai Heart.
- 1978: Received his Bachelor of Science degree from the University of Michigan
- 1982: Completed his Medical Degree at The Johns Hopkins School of Medicine
- 1982: Undertook his internship and residency at The New York Hospital-Cornell Medical Centre
- 1985: Began his first cardiology fellowship at the Cedars-Sinai Medical Centre
- 1988: Began his second cardiology fellowship at Saint Luke’s Mid-America Heart Institute
- 1989: Appointed Director of Interventional Cardiology at The Cardiovascular Institute, El Camino Hospital and Stanford University Medical Center
- 1998: Made Director of the Cardiovascular Training and Education Center at the Washington Hospital Center
- 1998: Made Chairman of the Cardiovascular Research Foundation in New York
- 1999: Interventional Cardiology at Lenox Hill Hospital
- 2004: Appointed Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian
- Current: Professor of Medicine and Professor of Population Health Sciences and Policy at The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine, at Mount Sinai. Also the Director of Academic Affairs for Mount Sinai Heart, Mount Sinai Heart Health System.
Dr. Stone has been recognised by America's Top Doctors (book series): 3rd Edition, 4th Edition, 5th Edition, 6th Edition, 7th Edition, 8th Edition, 9th Edition, 10th Edition, 11th Edition, 12th Edition, 13th Edition, and 14th Edition
Also by: Top Doctors: New York Metro Area (book series): 7th Edition, 8th Edition, 9th Edition, 10th Edition, 11th Edition, 12th Edition, 13th Edition, 14th Edition, 15th Edition, 16th Edition, 17th Edition, 18th Edition.
New York Magazine: Top Doctors: 2004, 2005, 2006, 2007, 2008.
Castle Connolly America's Top Doctors (digital guide): 2016, 2017, 2018, 2019, 2020.
Top Doctors New York Metro Area (digital guide): 2016, 2017, 2018, 2019, 2020.
Areas of Speciality
- Interventional therapies of acute coronary syndromes and myocardial infarction
- Drug-eluting stents
- Antiplatelet and antithrombotic pharmacotherapies
- Transcatheter mitral valve repair and replacement
- New device angioplasty including atherectomy, distal embolic protection, thrombectomy, vascular brachytherapy, and stent grafts
- Saphenous vein graft therapies
- Intravascular imaging
- Chronic total occlusions
- Left atrial appendage closure
- Vulnerable plaque
- Contrast nephropathy
- Clinical trial design
- Regulatory issues